NHS52S04
NHS52S04: Ultra-Low-Power Bluetooth® Low Energy Solution With Arm® Cortex®-M33 TrustZone® for Medical IoT
Constant glucose balancing, endless dosing decisions: Diabetes management doesn't pause. It demands constant attention. For people living with the condition, that means a mind that never rests. Reducing that burden requires systems that can autonomously respond in real time, without constant user input.
For more than 20 years, Insulet and NXP have collaborated to advance insulin delivery — combining Insulet’s application expertise with NXP’s scalable processing, connectivity and security. Today, that collaboration powers the Omnipod® 5, a tubeless, wearable insulin pump that automatically adjusts insulin delivery in real time.
The Omnipod 5 uses a secure, low-power edge architecture to continuously analyze glucose data and adapt insulin delivery automatically, helping shift diabetes management from manual control to intelligent, automated support.
Sign in to access this content and additional site features.
Don’t have an account? Register now.An ultra-low-power Bluetooth® Low Energy 5.3 solution integrating an Arm® Cortex®-M33 microcontroller, wireless transceiver and flash on a single chip. It enables compact system design and supports continuous operation in wearable medical devices.
Built-in security features include Arm® TrustZone®, secure boot, cryptographic acceleration (AES, RSA, ECC and PUF-based key storage). These mechanisms help protect system integrity and secure device communication.
Low-power wireless technology that enables reliable communication between insulin delivery systems and continuous glucose monitoring (CGM) devices for real-time data exchange.
On-device data processing that enables predictable, real-time system responsiveness, reduces latency and limits reliance on external or cloud-based systems.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone or the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.